BRPI0418572A - composição farmacêutica revestida e sólida para uso veterinário e administração oral dos princìpios ativos de paladar desagradável e revestimento - Google Patents

composição farmacêutica revestida e sólida para uso veterinário e administração oral dos princìpios ativos de paladar desagradável e revestimento

Info

Publication number
BRPI0418572A
BRPI0418572A BRPI0418572-2A BRPI0418572A BRPI0418572A BR PI0418572 A BRPI0418572 A BR PI0418572A BR PI0418572 A BRPI0418572 A BR PI0418572A BR PI0418572 A BRPI0418572 A BR PI0418572A
Authority
BR
Brazil
Prior art keywords
coating
pharmaceutical composition
oral administration
solid
sweetener
Prior art date
Application number
BRPI0418572-2A
Other languages
English (en)
Inventor
Mario Oda Kokuta
Original Assignee
Laboratiorios K Nig S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratiorios K Nig S A filed Critical Laboratiorios K Nig S A
Publication of BRPI0418572A publication Critical patent/BRPI0418572A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO FARMACêUTICA REVESTIDA E SóLIDA PARA USO VEERINáRIO E ADMINISTRAçãO ORAL DOS PRINCìPIOS ATIVOS DE PALADAR DESAGRADáVEL E REVESTIMENTO. A presente invenção se relaciona a uma composiçãofarmacêutica sólida de uso veterinário para a administração oral dos princípios ativos de sabor desagradável e revestimento, onde tal composição inclui um núcleo comprimido que tem pelo menos um pricípio ativo e excipientes farmaceuticamente aceitáveis, bem como um revestimento que inclui pelomenos um edulcorante e pelo menos uma compressão coadjuvante. O revestimento tem uma espessura de 2 a 4 mm que cobre completamente o núcleo ativo. O revestimento de edulcorante pode ser, por exemplo, lêvedo de cerveja, glutamato monosódico , hidrocloreto de L-lisina, pó de proteina hidrolisada, pó de essência de fígado, essência pó de essência de carne, pó de essência de coração ou suas combinações, onde tal edulcorante está presente em uma quantidade entre 3 e 60% p/p comparado ao peso total do revestimento. A compressão coadjuvante pode ser, por exemplo, polivinil-pirrolidona, estearato de magnésio, amido de milho ou lactose monohidratada, onde tal coadjuvante está presente em uma quantidade entre 3 e 45% p/p comparada ao peso total do revestimento.
BRPI0418572-2A 2004-02-27 2004-02-27 composição farmacêutica revestida e sólida para uso veterinário e administração oral dos princìpios ativos de paladar desagradável e revestimento BRPI0418572A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2004/000023 WO2005081612A2 (en) 2004-02-27 2004-02-27 Solid and coated pharmaceutical composition, for veterinary use and for oral administration of active principles of disagreeable taste, and coat

Publications (1)

Publication Number Publication Date
BRPI0418572A true BRPI0418572A (pt) 2007-07-31

Family

ID=34891807

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418572-2A BRPI0418572A (pt) 2004-02-27 2004-02-27 composição farmacêutica revestida e sólida para uso veterinário e administração oral dos princìpios ativos de paladar desagradável e revestimento

Country Status (3)

Country Link
AR (1) AR047705A1 (pt)
BR (1) BRPI0418572A (pt)
WO (1) WO2005081612A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023013A1 (en) * 2007-08-13 2009-02-19 Alpharma, Inc. Praziquantel and cmetidine compositions and methods
HU231017B1 (hu) 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
CN107468711B (zh) * 2017-08-21 2020-02-11 河南省奥林特药业有限公司 一种从猪肝中提取精制肝精膏的制备方法

Also Published As

Publication number Publication date
WO2005081612A2 (en) 2005-09-09
AR047705A1 (es) 2006-02-08

Similar Documents

Publication Publication Date Title
US9192599B2 (en) Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
BR0315315A (pt) Método para tratar, prevenir ou controlar uma sìndrome mielodisplásica, método para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
RS20110564A2 (en) ONE-DAY OXYCODON FORMULATIONS
EP2453743B1 (en) N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
BR0317134A (pt) Composições e métodos de liberação de agentes farmacológicos
ME00347B (me) Dozirani oblik pramipeksola za upotrebu jedanput dnevno
JP2007512371A5 (pt)
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
NO20083104L (no) Fast preparat
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
DK1711169T3 (da) Coatede mikrodepottabletter med venlafaxinhydrochlorid
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
BRPI0418572A (pt) composição farmacêutica revestida e sólida para uso veterinário e administração oral dos princìpios ativos de paladar desagradável e revestimento
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2007027092A3 (en) Oral composition for moisturising skin
CA2429793A1 (en) Interferon therapeutic effect enhancer
AU2203401A (en) Formulations of adenosine a1 agonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 31/495, A61K 31/4985, A61K 31/517, A61K 47/42, A61K 47/46, A61K 9/28, A61P 25/22,A61P 33/00

Ipc: A61K 31/495 (2011.01), A61K 31/4985 (2011.01), A61

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.